Mid
N
NKTRAI Stock Diagnostic Report
Nektar Therapeutics drops as jury deliberates in Eli Lilly patent dispute over Rezpeg
Nektar Therapeutics shares fell ahead of the ruling in its Rezpeg patent dispute with Eli Lilly.
View Source Article ↗AI CATALYST SCORE45 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time